Merck Expands Hematology Portfolio with $6.7B Acquisition of Terns Pharmaceuticals
- Mar 25
- 1 min read
Rahway, NJ and Foster City, CA, March 25, 2026 (Business Wire) -- Merck has agreed to acquire Terns Pharmaceuticals in an all-cash transaction valued at approximately $6.7 billion. The deal adds TERN-701, an investigational oral therapy for chronic myeloid leukemia, to Merck’s oncology pipeline. The transaction is expected to close in the second quarter of 2026, pending customary conditions.
Read full article here.